Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
Scientific News
Genome Study Predicts DNA of the Whole of Iceland
Large genome databases are starting to reveal critical health information-even about people who have not contributed their DNA.
Genetic Mutation Helps Explain Why, In Rare Cases, Flu Can Kill
Study shows that immune response to flu can be affected by a rare genetic mutation.
New Autism-Causing Genetic Variant Identified
Novel approach expected to be useful for other diseases too.
Genetics Help Predict Heart Disease Risk, Statin Benefits
Researchers found that a set of genetic variants could identify people at risk for coronary heart disease and who would benefit most from statin therapy.
Kidney Cancer Detected Early With Urine Test
Washington University School of Medicine researchers have developed a noninvasive method to screen for kidney cancer by measuring the presence of proteins in the urine.
New Gene Influences Apple or Pear Shape, Risk of Future Disease
Duke researchers have discovered that a gene called Plexin D1 controls both where fat is stored and how fat cells are shaped.
Molecule Controls Stem Cell Plasticity By Boosting Gene Expression
Sox9 appears to lead the activation of super-enhancers that boost genes associated with stem cell plasticity.
The First Fine-Scale Genetic Map Of The British Isles
Many people in the UK feel a strong sense of regional identity, and it now appears that there may be a scientific basis to this feeling, according to a landmark new study into the genetic makeup of the British Isles.
Gene Discovery Provides Clues To How TB May Evade The Immune System
The largest genetic study of TB susceptibility to date has led to a potentially important new insight into how the pathogen manages to evade the immune system.
Honey, I Shrunk The Ants: How Environment Controls Size
Ground breaking epigenetics research has implications for everything from cancer to farming.
Return
Multi Center Validation of a New Molecular Diagnostic Assay for Accurate and Rapid Screening of JAK2 V617F Mutation
Fabienne Hermitte, CSO, Ipsogen, speaking at the Molecular Diagnostics World Congress 2007
Date Posted: Monday, May 19, 2008
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Related Content

IPSOGEN Expands its U.S. Presence through Licensing Agreement with Quest Diagnostics
Ipsogen entered a non-exclusive license agreement with Quest for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Tuesday, October 07, 2008
IPSOGEN Expands its U.S. Presence Through Licensing Agreement with Quest Diagnostics
Ipsogen SA, a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announced a non-exclusive license agreement with Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Monday, October 06, 2008
Ipsogen Launches MapQuant Dx™ Genomic Grade Test to Analyze Chemotherapy Results
The Company expects that by improving the accuracy of tumor grading, the test could spare tens of thousands chemotherapy treatments per year.
Monday, June 02, 2008
Ipsogen Announces Three Studies at the American Society of Clinical Oncology Meeting
The results from the studies extend the utility of the Genomic Grade index for predicting response to chemotherapy in breast cancer.
Monday, May 26, 2008
IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision
IPSOGEN signed a license agreement with Universite Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™.
Monday, January 28, 2008
Ipsogen Reports Recommendation of JAK2V617F Mutation Screening in WHO 2008 Criteria and Point-of-Care Diagnostic Algorithms
The 2008 revision of the WHO document on the classification of CMPDs has incorporated new information on the molecular pathogenesis of BCR–ABL negative myeloproliferative disorders including the screening for JAK2V617F mutation.
Tuesday, January 22, 2008
IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA
IPSOGEN grants LabCorp non-exclusive rights to offer an assay for the diagnosis of a group of leukemias caused by JAK2 gene variations.
Tuesday, September 11, 2007
Ipsogen Grants Exclusive License to Warnex to Market a Leukemia Molecular Diagnostic Service in Canada
Ipsogen grants Warnex exclusive rights to market a service for the diagnosis and the classification of a group of leukemias.
Thursday, August 16, 2007
Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5
These results concern the identification on 323 patient samples.
Monday, February 27, 2006
 
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters